According to the announcement of Henlius on Apr. 25, 2019, the marketing application of the trastuzumab HLX02 has been accepted by NMPA, with the acceptance No. of CXSS1900021 and the indications applied for being early-stage HER2+ breast cancer, metastatic breast cancer, and metastatic gastric cancer. HLX02 is one of the 4 core products of Henlius and is being conducted a global Phase 3 clinical trial in China, Poland, Ukraine, and the Philippines. The marketing of the drug in China will mark a milestone of the product’s development and commercialization. Roche’s trastuzumab has so far been marketed for 21 years in the world and 17 years in China, with global sales reaching CHF6.982 billion and sales in China reaching about RMB2.7 billion in 2018. The marketing of HLX02 in China will benefit more cancer patients to effectively reduce patients’ medical payment pressure!
